Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials
No significant differences in mirabegron efficacy were noted between groups with OAB with and without CRC. Low prevalence of cardiac TEAEs was noted, which indicates that mirabegron was well tolerated in both groups.
Authors
- Amy Lockefeer
- Swapneel Anaokar
- Arianne Schild
- Mikkel Fode
Institutions
- Astellas Pharma (Japan) (JP)
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- Astellas Pharma (United Kingdom) (GB)
- Astellas Pharma (Netherlands) (NL)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- European Urology Focus
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.euf.2026.01.010
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00